Insider Trading Alert - EXAM, EXA And CPHD Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 4, 2015, 76 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $203.25 to $160,379,000.00.

Highlighted Stocks Traded by Insiders:

ExamWorks Group (EXAM) - FREE Research Report

Presby J Thomas, who is Director at ExamWorks Group, sold 20,000 shares at $39.44 on June 4, 2015. Following this transaction, the Director owned 64,633 shares meaning that the stake was reduced by 23.63% with the 20,000-share transaction.

Campbell Wesley, who is President at ExamWorks Group, sold 5,172 shares at $39.23 on June 4, 2015. Following this transaction, the President owned 43,837 shares meaning that the stake was reduced by 10.55% with the 5,172-share transaction.

Fernandez de Castro Jose Miguel, who is CFO, Senior EVP and Treasurer at ExamWorks Group, sold 4,850 shares at $39.23 on June 4, 2015. Following this transaction, the CFO, Senior EVP and Treasurer owned 53,597 shares meaning that the stake was reduced by 8.3% with the 4,850-share transaction.

Patmore Crystal B., who is Executive Vice President at ExamWorks Group, sold 3,233 shares at $39.23 on June 4, 2015. Following this transaction, the Executive Vice President owned 27,400 shares meaning that the stake was reduced by 10.55% with the 3,233-share transaction.

Kozlowski Kevin J., who is Chief Information Officer at ExamWorks Group, sold 3,880 shares at $39.23 on June 4, 2015. Following this transaction, the Chief Information Officer owned 32,883 shares meaning that the stake was reduced by 10.55% with the 3,880-share transaction.

The shares most recently traded at $39.28, up $0.05, or 0.13% since the insider transaction. Historical insider transactions for ExamWorks Group go as follows:

  • 4-Week # shares sold: 16,900
  • 12-Week # shares sold: 41,900
  • 24-Week # shares bought: 13,500
  • 24-Week # shares sold: 41,900

The average volume for ExamWorks Group has been 264,700 shares per day over the past 30 days. ExamWorks Group has a market cap of $1.7 billion and is part of the financial sector and insurance industry. Shares are down 4.23% year-to-date as of the close of trading on Thursday.

ExamWorks Group, Inc., together with its subsidiaries, provides independent medical examinations (IMEs), peer and bill reviews, Medicare compliance, and other related services in the United States, Canada, the United Kingdom, and Australia. The company has a P/E ratio of 210.2. Currently, there are 3 analysts who rate ExamWorks Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXAM - FREE

TheStreet Quant Ratings rates ExamWorks Group as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including premium valuation, poor profit margins and generally higher debt management risk. Get the full ExamWorks Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Exa (EXA) - FREE Research Report

Remondi Stephen A., who is CEO and President at Exa, sold 10,000 shares at $10.85 on June 4, 2015. Following this transaction, the CEO and President owned 486,974 shares meaning that the stake was reduced by 2.01% with the 10,000-share transaction.

The shares most recently traded at $10.42, down $0.43, or 4.16% since the insider transaction. Historical insider transactions for Exa go as follows:

  • 4-Week # shares bought: 12,000
  • 4-Week # shares sold: 1,116
  • 12-Week # shares bought: 12,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 12,000
  • 24-Week # shares sold: 50,000

The average volume for Exa has been 38,200 shares per day over the past 30 days. Exa has a market cap of $158.5 million and is part of the technology sector and computer software & services industry. Shares are down 6.58% year-to-date as of the close of trading on Thursday.

Exa Corporation develops, sells, and supports simulation software and services for vehicle manufacturers worldwide. Currently, there are 3 analysts who rate Exa a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXA - FREE

TheStreet Quant Ratings rates Exa as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Exa Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cepheid (CPHD) - FREE Research Report

Kocmond Warren C Jr, who is EVP & Chief Operating Officer at Cepheid, sold 1,027 shares at $55.13 on June 4, 2015. Following this transaction, the EVP & Chief Operating Officer owned 16,250 shares meaning that the stake was reduced by 5.94% with the 1,027-share transaction.

The shares most recently traded at $55.20, up $0.07, or 0.13% since the insider transaction. Historical insider transactions for Cepheid go as follows:

  • 4-Week # shares sold: 7,492
  • 12-Week # shares sold: 7,492
  • 24-Week # shares sold: 7,492

The average volume for Cepheid has been 485,900 shares per day over the past 30 days. Cepheid has a market cap of $4.1 billion and is part of the technology sector and electronics industry. Shares are up 3.2% year-to-date as of the close of trading on Thursday.

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. Currently, there are 12 analysts who rate Cepheid a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPHD - FREE

TheStreet Quant Ratings rates Cepheid as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Cepheid Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs